Leslie J Berg

 

 

 

 

UMassMed Faculty Page

Inventions:

Title: Immunotherapy for T Cell-Mediated Autoimmune Diseases Using ITK Inhibitors. UMMS10-05; Patent Pending. 

• The present disclosure is based, in part, on the discovery that interleukin-2-inducible T cell kinase (ITK) and CD28 signals regulate auto-reactive T cell trafficking and that organ-specific T cell mediated autoimmune diseases such as Type 1 diabetes and multiple sclerosis. Accordingly, the present specification provides methods of treating organ-specific T cell mediated autoimmune diseases by inhibiting ITK with a therapeutically effective amount of an ITK inhibitor, e.g., BMS509744, ibrutinib, 10n, 2-amino-5-(thioaryl)thiazole, 5 aminomethylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene.

  • Technology: Small Molecules
    
  • Applications: Type I Diabetes, Type II Diabetes, Immunology, Multiple Sclerosis

 

Innovation Topics: Small Molecules, Type I Diabetes, Type II Diabetes, Immunology, Multiple Sclerosis